Table 3 Kaplan-meier analysis of time to first moderate/severe exacerbation and to premature withdrawal of patients from the study (ITT Population)
FP/SAL 250/50 μg | SAL 50 μg | Hazard Ratio (FP/SAL:SAL) | |
|---|---|---|---|
(N = 314) | (N = 325) | (95% CI) | |
Cumulative no. (%) patients with moderate/severe exacerbation | 102 (32) | 115 (35) | |
% probability (95% CI) of moderate/severe exacerbation | 45.2 (36.8, 54.5) | 47.1 (40.6, 54.2) | 0.83 (0.63, 1.09) |
Cumulative no. (%) patients withdrawing from the study | 98 (31) | 119 (37) | |
% probability (95% CI) of withdrawal from the study | 31.7 (26.7, 37.3) | 37.1 (32.0, 42.7) | 0.87 (0.67, 1.13) |